NeoMedLight develops innovative medical devices designed for phototherapy. 
The company owns a unique and exclusive technology: the emission of light through woven optical fibers: the Lightex®. 
NeoMedLight is committed to the treatment and prevention of oral mucositis and radiodermatitis, a huge unmet clinical need.
Mucositis and radiodermatitis are the most common and debilitating side effects of chemotherapy and radiotherapy reported by cancer patients.
CareMin650™ is an innovative solution leveraging our innovative Lightex® technology indicated for the prevention and treatment of mucositis and dermatitis in cancer patients.
The CareMin650™ system allows patients to be treated safely, with precise control of treatment parameters and in a reproducible and consistent manner independent of the operator.
The CareMin650™ is the latest innovation in Photobiomodulation for the treatment of cancer patients.

NeoMedLight

Org chart

Teams

Offices